Yesha H. Parekh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yesha H. Parekh has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Erin P. McDonnell
Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
2 shared publications - Martin J. Blaser
Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, USA
2 shared publications - Nicole J. Altomare
Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
2 shared publications - Payal D. Parikh
For more information on this article, contact Thomas A. Nahass at [ protected]
2 shared publications - Mark H. Lazar
Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
1 shared publication - Ram C. Gowda
Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
1 shared publication
Latest Publications
- Open Access
Recurrence of Upper Extremity Deep Vein Thrombosis Secondary to COVID-19
Infection with SARS-CoV-2 leading to COVID-19 induces hyperinflammatory and hypercoagulable states, resulting in arterial and venous thromboembolic events. Deep vein thrombosis (DVT) has been well reported in COVID-19 patients. While most DVTs occur in a lower extremity, involvement of the upper extremity is uncommon. In this report, we describe the first reported patient with an upper extremity DVT recurrence secondary to COVID-19 infection.
Open AccessRecurrence of Upper Extremity Deep Vein Thrombosis Secondary to COVID-19
Infection with SARS-CoV-2 leading to COVID-19 induces hyperinflammatory and hypercoagulable states, resulting in arterial and venous thromboembolic events. Deep vein thrombosis (DVT) has been well reported in COVID-19 patients. While most DVTs occur in a lower extremity, involvement of the upper extremity is uncommon. In this report, we describe the first reported patient with an upper extremity DVT recurrence secondary to COVID-19 infection.
- Open Access
COVID-19 as a Trigger of Recurrent Guillain–Barré Syndrome
Coronavirus 2019 (COVID-19) has been reported to trigger Guillain–Barré syndrome (GBS). While uncommon, recurrent GBS (rGBS) episodes, triggered by antecedent viral infections, have been reported in a small proportion of GBS patients, here we describe a patient with a recurrent case of GBS, occurring secondary to COVID-19 infection. Before this patient’s episode, he had two prior GBS flares, each precipitated by a viral infection followed by complete recovery besides intermittent paresthesias. We also consider the nosology of this illness in the spectrum of rGBS and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with their differing natural histories, prognosis, and therapeutic approaches. For patients who have a history of inflammatory demyelinating polyradiculopathies who develop COVID-19, we recommend close observation for neurologic symptoms over the next days and weeks.
Open AccessCOVID-19 as a Trigger of Recurrent Guillain–Barré Syndrome
Coronavirus 2019 (COVID-19) has been reported to trigger Guillain–Barré syndrome (GBS). While uncommon, recurrent GBS (rGBS) episodes, triggered by antecedent viral infections, have been reported in a small proportion of GBS patients, here we describe a patient with a recurrent case of GBS, occurring secondary to COVID-19 infection. Before this patient’s episode, he had two prior GBS flares, each precipitated by a viral infection followed by complete recovery besides intermittent paresthesias. We also consider the nosology of this illness in the spectrum of rGBS and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with their differing natural histories, prognosis, and therapeutic approaches. For patients who have a history of inflammatory demyelinating polyradiculopathies who develop COVID-19, we recommend close observation for neurologic symptoms over the next days and weeks.